You are here: Industry Insights > RSV

News List

Great Market Potential: Important Nodes in the Domestic RSV Pharmaceutical Field Xiaoyaowan
December 14, 2023
Respiratory syncytial virus (RSV) is a common enveloped RNA virus that circulates in the winter and spring. It is mainly transmitted by direct contact with the nasal secretions and respiratory droplets of infected individuals.
Hope for Africa in fight against RSV and new vaccine shows promise SHEM OIRERE
September 01, 2020
Africa’s hope of further reducing the neonatal deaths estimated at 28 per 1,000 live births, has received a major boost...
Texas Children's Hospital announces COVID-19 vaccine requirement for workforce members prnewswire
August 12, 2021
Today, Texas Children's Hospital announced it will require all members of its workforce to be vaccinated against COVID-19.
FDA Fast Track designation given to mRNA RSV vaccine europeanpharmaceuticalreview
August 06, 2021
Moderna’s mRNA respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345, gains Fast Track designation in adults over 60 years old.
Troubling Rise Seen in Both COVID-19, RSV Cases Among Children drugs
August 03, 2021
A rise in cases of respiratory syncytial virus (RSV) is unfolding just as COVID-19 infections are increasing among children.
Nirsevimab MEDLEY Phase II/III Trial Demonstrated Favourable Safety and Tolerability Profile in Infants at High Risk of RSV drugs
July 08, 2021
The MEDLEY Phase II/III trial evaluated the safety and tolerability of nirsevimab compared to Synagis (palivizumab) when given to infants at high risk of respiratory syncytial virus (RSV) entering their first RSV season.
Positive topline results for nirsevimab in RSV pharmatimes
April 27, 2021
Sanofi and AstraZeneca’s (AZ) monoclonal antibody (mAb) nirsevimab reached its primary endpoint in a Phase III trial, demonstrating protection against respiratory syncytial virus disease (RSV) in healthy infants.
Icosavax raises funding to advance RSV/hMPV vaccine programme pharmaceutical-technology
April 08, 2021
Icosavax has raised $100m through a Series B financing round to support the development of its bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) vaccine programme through initial clinical studies.
Abbott Receives EUA for PCR Assay That Detects, Differentiates SARS-CoV-2, Flu, RSV in One Test americanpharmaceuticalreview
March 11, 2021
Abbott announced U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the company's Alinity™ m Resp-4-Plex molecular assay to detect and differentiate SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) ...
Sanofi’s RSV treatment nirsevimab awarded PIM pharmatimes
January 22, 2021
Sanofi’s nirsevimab has been awarded a Promising Innovative Medicine (PIM) designation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for the prevention of respiratory syncytial virus (RSV) associated lower respiratory ...

Previous page 1 2 3 4 Next page